ProKidney Corp. (PROK)
ProKidney Corp. operates in the Biotechnology industry of the Healthcare sector, headquartered in Winston-Salem, NC, US. The stock last traded at $1.48, down 8.07% on the session, giving a market capitalisation of $497.7M. On trailing twelve-month figures it carries a trailing P/E of -2.60, a net margin of -10599.8%. Its beta of 1.72 implies it has historically moved more than the broad market.
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
ProKidney Corp. is most often compared with the following Healthcare names: